Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants

In response to the public health emergency posed by COVID-19, NHS England and NHS Improvement, have set out the interim clinical commissioning position for passive immunisation with palivizumab against respiratory syncytial virus (RSV) in at-risk pre-term infants.

Source:

NHS England